Table 2.

Laboratory values and radiographic findings at the admission of COVID-19 patients

	Normal range	Total (n = 107)	Survivors (n = 88)	Non-survivors (n = 19)	P value
White blood cell count, × 109/L	3.5–9.5	4.6 (3.7–6.1)	4.4 (3.4–5.8)	6.7 (4.6–10.3)	0.004*
Neutrophil count, × 109/L	1.8–6.3	3.1 (2.1–4.7)	2.8 (2.0–3.9)	5.4 (3.2–8.5)	< 0.001*
Lymphocyte count, × 109/L	1.1–3.2	0.9 (0.7–1.2)	0.9 (0.7–1.3)	0.8 (0.5–1.1)	0.121
Platelet count, × 109/L	125–350	175 (129–200)	178 (139–207)	122 (83–178)	0.006*
Prothrombin time, s	9.4–12.5	12.8 (11.9–13.5)	12.9 (12.0–13.5)	12.6 (11.9–13.5)	0.813
Activated partial thromboplastin time, s	25.1–36.5	31.7 (29.4–33.9)	31.7 (29.5–33.5)	32.7 (27.5–37.0)	0.850
D-dimer, mg/L	0–500	203 (121–358)	191 (108–327)	439 (202–1991)	0.003*
Creatine kinase, U/L	< 171	90 (54–138)	86 (53–121)	142 (87–325)	0.022*
Creatine kinase-MB, U/L	< 25	14 (10–18)	13 (9–16)	18 (13–44)	0.008*
Lactate dehydrogenase, U/L	125–243	236 (176–369)	227 (171–329)	456 (254–588)	0.010*
Alanine aminotransferase, U/L	9–50	23 (16–39)	22 (15–34)	47 (22–66)	0.002*
Aspartate aminotransferase, U/L	15–40	31 (24–47)	29 (23–41)	67 (38–90)	< 0.001*
Total bilirubin, mmol/L	5–21	9.8 (8.4–14.1)	9.5 (8.4–12.9)	11.3 (9.4–20.7)	0.069
Blood urea nitrogen, mmol/L	2.8–7.6	4.2 (3.2–5.6)	3.9 (3.0–4.7)	6.1 (4.9–10.5)	< 0.001*
Creatinine, μmol/L	64–104	71 (60–86)	68 (58–83)	87 (71–130)	< 0.001*
Hypersensitive troponin I, > 26.2 pg/mL, no. (%)	< 26.2	6 (5.6)	1 (1.1)	5 (26.3)	0.001*
Multi-lobar involvement on initial radiographs, no. (%)	NA	90 (84.1)	73 (83.0)	17 (89.5)	0.731
Bilateral involvement on radiographs during hospitalization, no. (%)	NA	105 (98.1)	86 (97.7)	19 (100.0)	1.000

Data are median (IQR) or n (%). P values indicate differences between survivors and non-survivors. P < 0.05 was considered significant. Laboratory values and radiographic findings were collected at admission except that the bilateral involvement on radiographs was collected during hospitalization

MB muscle and brain type, NA not available